Analyst Stacy Ku of TD Cowen maintained a Buy rating on Aurinia Pharmaceuticals, with a price target of $17.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Stacy Ku has given her Buy rating due to a combination of factors, primarily focusing on the promising sales trajectory and market potential of Aurinia Pharmaceuticals’ key product, Lupkynis. The third-quarter sales of Lupkynis exceeded expectations, reaching approximately $70.6 million, which was above the consensus estimate. This strong performance has led management to increase their 2025 sales guidance, reflecting confidence in continued growth despite a reduced sales force.
Additionally, the positive feedback from key opinion leaders (KOLs) suggests that Lupkynis will see steady adoption as healthcare providers gain more experience with the drug. The updated guidelines from the American College of Rheumatology (ACR) are also expected to support its use in first-line settings, enhancing its role in the treatment of lupus nephritis. Although there is some disappointment regarding Aurinia’s decision to remain independent, the long-term potential of Lupkynis and its expected market penetration reinforce the Buy rating.
In another report released on November 1, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $15.00 price target.